ALSO NOTED: New Roche CEO maps strategy; StemCells backs off buyout; and much more...

> Roche's incoming CEO, Severin Schwan, sees a continued emphasis on personalized medicine and says he also isn't anticipating any big mergers. Report

> After several months of negotiations, StemCells has backed off its bid to acquire Progenitor Cell Therapy, a cell processing service provider. Talks foundered after the two companies proved "unable to reach agreement on mutually acceptable terms and conditions," says StemCells. StemCells made a $3.8 million loan to Progenitor during a period of exclusivity to complete due diligence for the deal. That money is being repaid and Progenitor will continue to supply its services to StemCells. Release

> Indevus Pharmaceuticals CEO Glenn Cooper is planning to retire by September 1. Cooper spent 15 years at Indevus, which has begun the search process to find his successor. Release

> The Animal Health Division of Bayer HealthCare AG and Juvaris BioTherapeutics have executed a broad-based licensing agreement. Under the terms of the agreement, Bayer HealthCare will have complete access in the veterinary field to the Juvaris mono-immunotherapy and vaccine technology, which is being developed by Juvaris for human health care. Release

> A joint-venture company, StemCyte India Therapeutics, will provide stem cell therapies derived from umbilical cord blood to treat patients with certain malignant blood disorders. Release

> Bayer had the Yasmin rug pulled out from under it yesterday. A U.S. court voided the contraceptive's key patent, leading the German conglomerate to revise its 2008 profit expectations downward. Report

> The Supreme Court came and saw and voted but left no clarity on pre-emption behind. Because Chief Justice John Roberts sat out the case, the vote ended in a 4-4 tie. Report

> Here's why drug companies spend billions on DTC ads every year: They work. Report

And Finally... A Canada-U.S. research team has solved a major genetic mystery: How a protein in some people's DNA guards them against killer immune diseases such as HIV. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.